

# EXERCISE OF WARRANTS OF SERIES TO2

EXERCISE PERIOD: 21 NOVEMBER - 5 DECEMBER 2024

## IMPORTANT INFORMATION

This information document has been prepared by Curasight A/S ("Curasight" or the "Company"). The reader is asked to read the prospectus published by Curasight on 12 September 2024, in connection with the Company's rights issue, for a description of the risks associated with an investment in the Company. The prospectus is available for download on the Company's website ([www.curasight.com](http://www.curasight.com)).

## Curasight A/S

Curasight A/S ("Curasight") is a pioneering company developing an innovative imaging and therapeutic platform based on the urokinase-type plasminogen activator receptor (uPAR). This cutting-edge technology effectively minimizes radiation exposure to healthy tissues by combining targeted uTREAT<sup>®</sup> radiation therapy with precise uTRACE<sup>®</sup> diagnostics. Curasight has successfully completed or is currently conducting multiple investigator-initiated phase II clinical trials. The company is currently engaged in a phase II trial for prostate cancer as part of a global partnership with Curium, the world's leading radiopharmaceutical company. Additionally, Curasight is committed to advancing data generation for both uTRACE and uTREAT across various cancers, including prostate cancer, bladder cancer, glioblastoma (brain cancer), neuroendocrine tumors (NET), head and neck cancer, non-small cell lung cancer (NSCLC), and pancreatic cancer.

Through the exercise of warrant of series TO2, Curasight can receive proceeds at a maximum of approximately DKK 42.4 million. The proceeds raised through the exercise of TO2 will support several strategic initiatives:

- Continued clinical development of uTRACE<sup>®</sup> including the clinical trial with uTRACE<sup>®</sup> in prostate cancer, partnered with Curium - approximately 50 percent of the proceeds from the warrant exercise.
- Initiate, plan and enroll patients in therapeutic programs with uTREAT<sup>®</sup> - approximately 30 percent of the proceeds from the warrant exercise.
- Working capital and general corporate purposes, including broadening the foundation of the business and organization to maximize value creation - approximately 20 percent of the proceeds from the warrant exercise.

## THE OFFER IN BRIEF

<b>Exercise period:</b>	21 November - 5 December 2024.
<b>Exercise price:</b>	DKK 11.50 per share.
<b>Last day of trading in TO2:</b>	3 December 2024.
<b>Number of outstanding shares prior to warrant exercise:</b>	20,682,427 shares.
<b>Issue volume:</b>	If warrants of series TO2 are fully exercised, approximately DKK 42.4 million will be added to the Company before issue costs.
<b>ISIN-code for TO2:</b>	DK0063183207.

## TERMS IN SHORT

There are 3,683,814 issued warrants of series TO2. Holders of warrants of series TO2 have the right to subscribe for one (1) new share in Curasight A/S ("Curasight") at a price of DKK 11.50 per share for each warrant. Subscription with the support of warrants of series TO2 can take place during the period from and including 21 November 2024 to and including 5 December 2024. Subscription must take place by simultaneous cash payment no later than on 5 December 2024.

**As a warrant holder, you need to decide whether to accept the offer. This is how you exercise your warrants of series TO2:**

In order for your warrants not to expire worthless, you are required to subscribe for new shares, supported by warrants, by 5 December 2024 at the latest or sell your warrants by 3 December 2024 at the latest. All warrant holders should consult with their bank to confirm the final subscription date to ensure the opportunity is not missed. Subscription applications should be submitted directly through each respective bank.

**You can have your warrants registered in the following way:**

In a securities depository in a bank or with another administrator (for example, Avanza or Nordnet), in an investment savings account (ISK) or a capital insurance (KF). Your warrants are then trustee-registered.

Subscription and payment of new shares, with the support of warrants, must be made to the respective bank or other administrator where the warrants are registered. Subscription and payment shall be made in accordance with the instructions provided by each such bank or trustee. Usually the bank/custodian sends out a digital notice to the account holder, otherwise it is generally sufficient to log in to the securities depository from the first day of the exercise period to receive instructions on how to use warrants to subscribe for new shares. Please contact your bank or trustee if you cannot find these instructions. Note that banks and other administrators may set different time limits for subscription, therefore it is recommended that you contact your bank/administrator early in the usage period to obtain information about subscription and payment. Subscribed and paid shares may be registered in your securities depository as "interim shares" or "MIDL"

until registration of the issue is completed with the Danish Business Authority, whereupon interim shares are automatically exchanged for ordinary shares in Curasight.

### Important dates for warrants of series TO2



**NOTE - In order for your warrants not to expire worthless, it is required that you actively subscribe for shares no later than 5 December 2024 or sell your warrants no later than 3 December 2024.**

For any questions regarding warrants of series TO2, please contact Sedermera. Sedermera act as financial advisor for Curasight in connection with warrant exercise. DLA Piper Denmark Law Firm P/S acts as legal adviser. Danske Bank acts as settlement agent.

**Sedermera Corporate Finance AB**

Phone: +46 (0)40-615 14 10

E-mail: cf@sedermera.se

**Danske Bank**

E-mail: prospekter@danskebank.dk